MarketPulse
P

$PRAX

7 articles found
6 positive
0 negative
1 neutral
BenzingaBenzinga··Vandana Singh

Praxis Precision Surges on FDA Nod for Essential Tremor Treatment

Praxis Precision shares surge 7.15% after FDA accepts essential tremor drug application with January 2027 decision target and positive Phase 3 results.
PRAXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Praxis Precision Medicines Posts Breakthrough Results for Rare Epilepsy Gene Therapy

Praxis reports 77% placebo-adjusted seizure reduction in SCN2A epilepsy treatment with no serious safety events, advancing precision neurotherapy.
PRAXIONSclinical trialprecision medicine
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 700% as Top Fund Trims Position Yet Doubles Down

Cormorant Asset Management sold $PRAX shares for $9.3M in Q4, yet position surged $227M in value. Stock remains fund's largest holding at $280M.
EYPTPRAXABVXFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling Praxis Stock Soars 700% as Major Fund Doubles Down With $266M Bet

Deerfield Management boosts $PRAX stake to $266M as biotech stock surges 685% annually. Company eyes $20B+ pipeline revenue potential with two FDA applications pending.
PRAXFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Praxis, Stock Rallies 320%

Perceptive Advisors doubles investment in Praxis Precision Medicines to $588M, now largest holding. Stock surges 320% amid FDA submissions and strong cash position.
PRAXFDA approvalinstitutional investment
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying